Last reviewed · How we verify
RPV-LA Loading Dose
RPV-LA (rilpivirine long-acting) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase to prevent viral replication.
RPV-LA (rilpivirine long-acting) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase to prevent viral replication. Used for HIV-1 infection in treatment-naïve or virologically suppressed adults (as part of combination antiretroviral therapy).
At a glance
| Generic name | RPV-LA Loading Dose |
|---|---|
| Also known as | Rilpivirine Long-Acting Injectable |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | Non-nucleoside reverse transcriptase inhibitor (NNRTI) |
| Target | HIV-1 reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Rilpivirine is an NNRTI that binds to HIV-1 reverse transcriptase and inhibits its enzymatic activity, preventing the conversion of viral RNA to DNA and thus blocking HIV replication. The long-acting (LA) formulation uses nanosuspension technology to provide sustained drug release, allowing for less frequent dosing (monthly or bimonthly injections) compared to daily oral tablets. The loading dose regimen establishes therapeutic plasma concentrations rapidly before transitioning to maintenance dosing.
Approved indications
- HIV-1 infection in treatment-naïve or virologically suppressed adults (as part of combination antiretroviral therapy)
Common side effects
- Injection site reactions (pain, erythema, induration)
- Headache
- Nausea
- Rash
- Diarrhea
- Elevated liver enzymes
Key clinical trials
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study
- The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE (PHASE3)
- A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects (PHASE2)
- Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study (PHASE2)
- A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed (PHASE3)
- Long-Acting Treatment in Adolescents (LATA) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: